AI Article Synopsis
- Implantable cardioverter-defibrillators (ICDs) help prevent sudden cardiac death (SCD) and enhance survival for patients with serious heart rhythm issues or those at high risk for SCD.
- Despite their benefits, ICD patients sometimes experience inappropriate shocks, which can lead to adverse effects such as increased anxiety, decreased quality of life, and even higher mortality rates.
- The article focuses on the importance of careful programming and operational decisions by physicians to optimize the effectiveness and safety of ICD therapy based on clinical trial evidence.
Article Abstract
Implantable cardioverter-defibrillators (ICDs) reduce sudden cardiac death (SCD) and improve survival in patients with a history of life-threatening arrhythmia or sudden cardiac arrest, and in select populations at high risk of SCD due to ventricular arrhythmias. However, patients with ICDs may receive inappropriate or unnecessary shocks, which have been associated with pro-arrhythmia, psychological sequelae, poor quality of life, and increased mortality. The benefits and risks of ICD therapy are therefore directly impacted on by physician operative and programming decisions. This article aims to provide a detailed review of transvenous ICD programming as guided by clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccep.2024.06.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!